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burden of inﬂuenza by 79–85%. Estimated direct cost
savings (excluding the cost of vaccination) would be $47
per vaccinated child; indirect cost savings would be $199
per vaccinee. Assumed coverage levels of 40% and 80%
yielded similar ﬁndings. CONCLUSIONS: Routine vac-
cination of children and the resulting reduction in disease
transmission would reduce substantially the clinical and
economic burden of inﬂuenza in the US.
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Although inﬂuenza vaccination had been performed on
mandatory basis for Japanese school-aged children until
the mid of 1980s, thereafter the government changed the
policy into individual-initiated basis. It caused the recip-
ient rate of inﬂuenza vaccination rapidly decreasing. Con-
sequently, there emerged a controversy about vaccination
policy, mandatory vs. voluntary, for high-risk population.
OBJECTIVE: Evaluate cost-consequences of the contro-
versial strategies for inﬂuenza vaccination compared with
no vaccination for healthy school-aged children in Japan.
METHODS: A cost-consequence analysis was performed
by decision analytic modeling using data from the litera-
ture. The decision tree models a healthy school-aged child
facing the alternatives toward inﬂuenza: 1) individual-
initiated voluntary vaccination; 2) mandatory vaccination
in school; or 3) no vaccination. Direct costs included
medical costs for vaccination (the costs of the vaccine,
supplies, personnel, etc.), physician visits, and treatments.
Also, indirect costs were included in the form of lost pro-
ductivity in which the parents are burdened by taking
children to a physician’s ofﬁce for vaccination or staying
home to care for their ill children. The total cost of each
scenario was compared with that of no vaccination con-
sequence. We assumed the vaccine has no side effects 
for the base case, and then a sensitivity analysis was 
conducted to evaluate the impact of side effects with 
low-grade fever. RESULTS: Performing mandatory vacci-
nation could save US$13 (JY1571) per child vaccinated
comparing with no vaccination, whereas voluntary vac-
cination additionally cost US$36 (JY4428). Also, the total
cost of mandatory scenario had an advantage of marginal
saving of US$50 (JY6000) comparing to the voluntary
basis. The sensitivity analysis indicated that results in the
base case were rather robust. CONCLUSION: Manda-
tory vaccination for children in Japanese school could
have substantial cost savings. Considering the target pop-
ulation of 18,000,000 school children in Japan, turning
into mandatory is recommended with great potentiality
of economic impact on the society.
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OBJECTIVES: The World Health Report 2002 attributes
15% of the burden of disease associated with major risk
factors in developing countries to malnutrition and about
3% each to Vitamin A and zinc deﬁciency. Most of the
burden is from diarrhea and pneumonia in children aged
less than ﬁve years. This paper analyses the costs and
effectiveness of selected personal and non-personal cura-
tive and preventive interventions, singly and in com-
bination. METHODS: For each of 11 epidemiological
subregions, the population health impact for each inter-
vention or combination of interventions at different levels
of coverage has been evaluated using a state transition
model. Efﬁcacy data come from systematic reviews or
evaluations. Costs are estimated using the standardized
WHO ingredients approach. An intervention is consid-
ered cost-effective if the cost-effectiveness ratio is <3 GDP
per capita for the subregion. RESULTS: The highest
health gains from a single intervention are from case man-
agement for pneumonia and oral rehydration therapy.
The lowest costs are with fortiﬁcation with Vitamin A
and zinc. Cost-effectiveness ratios cluster in three groups
with fortiﬁcation with zinc and Vitamin A as the most
cost-effective, and provision of supplementary food 
and nutrition counseling as the least cost-effective. In
between are oral rehydration therapy, case management
for pneumonia and Vitamin A and zinc supplementation.
CONCLUSIONS: On the grounds of cost-effectiveness,
Vitamin A and zinc fortiﬁcation or supplementation
should be considered for routine provision, together 
with oral rehydration therapy and case management for
pneumonia.
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OBJECTIVES: To compare the clinical and economic
impact of oral TEL and CLA in adult outpatients with
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CAP. METHODS: In 2 independent, randomized,
double-blind, multicenter clinical studies, 1023 adult out-
patients (Study 1, n = 448; Study 2, n = 575) with CAP
received TEL 800mg once daily for 10 (Study 1) or 5 or
7 days (Study 2), or CLA 500mg twice daily for 10 days
(comparator regimen, both studies). Clinical and eco-
nomic outcomes were followed for four weeks. The
primary statistical hypothesis was equivalence of clinical
efﬁcacy (per-protocol populations). Economic outcomes
in the intent to treat populations were assessed by 
non-protocol-driven CAP-related resource use. Unit costs
were assigned as follows (Study 1/2): additional antibi-
otics/medications using 1999/2000 Redbook average
wholesale prices; physician visits/tests/procedures using
Medicare’s Resource Based Relative Value Scale; and 
hospitalizations using 1999/2000 American Hospital
Association national average daily rates for short-term
hospitalization. Data from the two studies were pooled
and analyzed. RESULTS: The clinical efﬁcacy of TEL 
and CLA was equivalent (88.8% [428/482] vs 90.1%
[272/302], respectively). Patients treated with TEL had
fewer CAP-related hospitalizations vs CLA patients
(13/612 [2.6%] vs 15/411 [3.6%], respectively). The
length of stay in hospital was shorter for TEL vs CLA
patients (16.8 vs 33.8 hospital days per 100 patients,
respectively). Concomitant antibiotics were required by
135/612 (22.1%) TEL vs 110/411 (26.8%) CLA patients.
The average per-patient cost of additional resource use
for TEL ($309) was considerably less than that for CLA
($622), with per-patient savings of $313 for TEL. Greater
savings were observed for the subset of patients aged 65
years: average per-patient cost of additional resource use
for TEL of $305 vs $896 for CLA, with per-patient
savings of $591 for TEL. CONCLUSIONS: TEL is an
effective therapy for outpatients with CAP and is associ-
ated with lower direct healthcare costs than CLA.
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OBJECTIVES: Treatment of CAP is becoming more 
difﬁcult because of changes in the antibiotic resistance
patterns of pathogens causing CAP, particularly S. 
pneumoniae. This purpose of this study is to assess the
economic impact of changes in hospitalization and mor-
tality rates in CAP due to antimicrobial resistance.
METHODS: The costs of CAP were determined from 
an administrative claims database from 1996–1998 for
an employed population and their dependents under the
age of 65 (N > 100,000). The economic impact of antibi-
otic resistance on CAP costs was simulated under differ-
ent scenarios. The simulations were based on the
assumptions that antibiotic resistance might increase the
mortality rate, the hospitalization rate, or both the mor-
tality and hospitalization rates in CAP. RESULTS: We
identiﬁed 7,249 episodes of CAP. The hospitalization rate
was 19.6% and the mortality rate among inpatient CAP
episodes was 9.1%. The average cost of treatment for an
inpatient episode of CAP (including all inpatient and out-
patient medical care) was $10,227. Costs for inpatients
who died during hospitalization ($15,822) were higher
than for episodes in which patients were discharged alive
($9,595). Increasing the mortality rate by an additional
5% (to 14.1%) led to a 3% increase in the total costs 
of treatment. Increasing the hospitalization rate from the
observed rate of 20% to 25% increased total costs by
28%. CONCLUSIONS: Simulations indicate that, if
antibiotic resistant organisms increase outpatient treat-
ment failures and resultant hospitalization rates for CAP,
there would be a substantial economic impact. The total
annual economic impact of treating CAP in the U.S. is
estimated to be $12.1 billion. If resistance leads to higher
mortality rates and hospitalization rates, the total annual
economic impact of treating CAP in the U.S. could rise
by 23% to $14.9 billion.
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OBJECTIVES: To evaluate the cost-effectiveness of line-
zolid, compared to teicoplanin, for serious gram-positive
infections from a randomized trial, which showed that
linezolid had superior efﬁcacy especially in bacteremia
(ICAAC 2001; L-1481), a trend toward shorter LOS
(ECCMID 2002; O140) and lower mean adjusted total
cost of treatment (SCCM 2003; 200). METHODS: Hos-
pitalized patients from 6 European (n = 227) and 7 South
American (n = 203) countries with serious gram-positive
infections including pneumonia, complicated skin/soft
tissue infections, or bacteremia were treated with line-
zolid (intravenous followed by optional oral) or
teicoplanin (intravenous followed by optional intra-
muscular) for up to 4 weeks, followed by up to 3 weeks
of observation. Investigator-assessed end-of-treatment
success/failure was used to determine effectiveness,
missing/indeterminate evaluations were either scored as
failures or imputed using logistic regressions. Resource
use during the 49-day study period was collected and
